Core Viewpoint - Scienture Holdings, Inc. has announced the FDA listing of two patents for its product Arbli, a novel oral liquid formulation of losartan, which is expected to enhance its market position and provide statutory exclusivity under the Hatch-Waxman Act [1][2][6]. Company Overview - Scienture Holdings, Inc. is a holding company focused on developing and distributing specialty pharmaceutical products that address unmet market needs [1][13]. - The company operates through its subsidiary, Scienture, LLC, which is dedicated to bringing unique specialty products to market [13]. Product Details - Arbli is the first FDA-approved ready-to-use oral liquid formulation of losartan, designed for patients over 6 years old, and is indicated for the treatment of hypertension and related conditions [3][4][8]. - The product is available in a 165 mL bottle with a peppermint flavor, has a shelf life of 18 months at room temperature, and does not require refrigeration [7]. Market Position - The patents for Arbli cover stable liquid formulations of losartan and methods of use, reinforcing Scienture's intellectual property position [2]. - Losartan is classified as an angiotensin receptor blocker (ARB) and is one of the most prescribed medications for hypertension, with annual sales of approximately $276 million and a prescription volume of 69 million in the U.S. market as of March 2025 [5]. Regulatory Milestone - The listing of Arbli in the FDA's Orange Book is considered a significant regulatory achievement for Scienture, validating its development efforts and enhancing its commercial pathway in the U.S. market [6][2].

Core Viewpoint - Cerence Inc. has filed a lawsuit against Microsoft and Nuance Communications for copyright infringement and breach of contract, focusing on its text-to-speech technology, which is crucial for its product offerings in automotive and other sectors [1][2][3]. Company Overview - Cerence Inc. is a global leader in AI-powered user experiences, particularly in the automotive and transportation industries, with over 500 million cars equipped with its technology [4]. - The company emphasizes its commitment to protecting its intellectual property rights and plans to defend its innovations vigorously [3][4]. Legal Context - The lawsuit aims to safeguard Cerence's significant investments in its intellectual property portfolio, particularly its text-to-speech technology, which is foundational to its operations [2][3]. - The action against Microsoft and Nuance is seen as necessary to uphold the company's culture of innovation and protect its market position as it expands beyond automotive applications [3].

As filed with the U.S. Securities and Exchange Commission on July 15, 2024. Registration No. 333-279771 Ontario, Canada 2834 Not Applicable (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specifie ...

FORM S-1 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. Employer Identification Number) 60 North 1400 West Centerville Utah 84014 (801) 298-1997 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Under The Securities Act of 1933 TRUGOLF HOLDINGS, INC. (Exact name of Registrant as specified ...

As filed with the U.S. Securities and Exchange Commission on January 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tenax Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 2834 26-2593535 (I.R.S. Employer Identification Number) Tenax Therapeutics, Inc. 101 Glen Lenn ...